Anti-PD1/PD-L1 monotherapy vs standard of care in patients with recurrent or metastatic head and neck squamous cell carcinoma
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Anti-PD1/PD-L1 monotherapy vs standard of care in patients with recurrent or metastatic head and neck squamous cell carcinoma
Authors
Keywords
-
Journal
MEDICINE
Volume 100, Issue 4, Pages e24339
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2021-01-29
DOI
10.1097/md.0000000000024339
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study
- (2020) R.L. Ferris et al. ANNALS OF ONCOLOGY
- Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort
- (2019) Neil H. Segal et al. EUROPEAN JOURNAL OF CANCER
- The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
- (2019) Ezra E. W. Cohen et al. Journal for ImmunoTherapy of Cancer
- The effects and safety of PD‐1/PD‐L1 inhibitors on head and neck cancer: A systematic review and meta‐analysis
- (2019) Bi‐Cheng Wang et al. Cancer Medicine
- Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
- (2018) Robert L. Ferris et al. ORAL ONCOLOGY
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy
- (2018) Dan P. Zandberg et al. EUROPEAN JOURNAL OF CANCER
- Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
- (2018) Ezra E W Cohen et al. LANCET
- Persistent Head and Neck Cancer Following First-Line Treatment
- (2018) Teresa Steinbichler et al. Cancers
- NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017
- (2017) David Adelstein et al. Journal of the National Comprehensive Cancer Network
- Cancer immunotherapy: the beginning of the end of cancer?
- (2016) Sofia Farkona et al. BMC Medicine
- Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
- (2016) Tanguy Y Seiwert et al. LANCET ONCOLOGY
- Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment
- (2016) Shanthi Marur et al. MAYO CLINIC PROCEEDINGS
- Global Epidemiology of Head and Neck Cancers: A Continuing Challenge
- (2016) Bhawna Gupta et al. ONCOLOGY
- Immunology and Immunotherapy of Head and Neck Cancer
- (2015) Robert L. Ferris JOURNAL OF CLINICAL ONCOLOGY
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2013) David Moher ANNALS OF INTERNAL MEDICINE
- Recognizing and reversing the immunosuppressive tumor microenvironment of head and neck cancer
- (2012) Charles C. L. Tong et al. IMMUNOLOGIC RESEARCH
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Head and Neck Cancer: Changing Epidemiology, Diagnosis, and Treatment
- (2009) Shanthi Marur et al. MAYO CLINIC PROCEEDINGS
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
- (2008) Jan B. Vermorken et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search